Syntec Optics (Nasdaq: OPTX) Enabling Optics for Near Vision Correction

Rhea-AI Summary

Syntec Optics (Nasdaq: OPTX) announced its involvement in enabling optics for clinical development of non-incisional vision correction technology targeting near vision problems. The company is leveraging its advanced optical manufacturing capabilities to support the development of less invasive alternatives to traditional treatments for presbyopia, a condition affecting approximately 128 million people in the U.S.

The global myopia and presbyopia treatment market, valued at $20.3 billion in 2025, is expected to grow further. Syntec's involvement in developing non-incisional optical solutions aims to provide safer, quicker, and more convenient treatment options compared to traditional surgical interventions, potentially improving quality of life for millions affected by age-related vision loss.

Positive

• Targeting large addressable market of 128 million people in U.S. with presbyopia
• Entering $20.3 billion global myopia and presbyopia treatment market
• Early involvement in development of innovative non-incisional vision correction technology

Negative

• None.

Insights

Medical Device Industry Analyst

Syntec Optics is entering the $20.3B vision correction market by manufacturing specialized optics for a non-surgical presbyopia treatment, representing strategic positioning but uncertain near-term impact.

Syntec's entry into the non-incisional presbyopia treatment space represents a strategic move into a substantial medical market. With presbyopia affecting an estimated 128 million Americans and a global treatment market valued at $20.3 billion, the company is targeting a significant unmet need with considerable commercial potential.

The company is positioning itself as a manufacturing partner rather than an end-product developer—a business model that leverages their core competencies in precision optics while minimizing direct regulatory exposure. The specialized nature of medical-grade optics typically commands premium pricing due to stringent quality requirements, potentially offering higher margins than consumer applications.

However, investors should note several unaddressed factors in this announcement. The press release doesn't specify the current stage of clinical development, the identity of their customer, projected timeline to market approval, or potential revenue impact. Medical device development typically involves extended clinical validation periods and regulatory review, suggesting any material financial benefit could be years away.

The presbyopia treatment landscape is evolving beyond traditional corrective lenses, with pharmaceutical approaches (prescription eye drops) already receiving FDA approval and competing optical technologies under development. Syntec's success will depend heavily on their customer's ability to navigate clinical development and secure regulatory clearance.

While this announcement indicates promising diversification into higher-value medical applications, the absence of specific financial projections, development timelines, or contract details suggests a measured outlook is appropriate. This appears to represent longer-term strategic positioning rather than a catalyst for near-term financial performance.

ROCHESTER, NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a leading provider of technology products to defense, biomedical, communications, and consumer industry leaders, today announced it is enabling optics for the clinical development of innovative, non-incisional optics-based refractive error correction to recover near vision. This common age-related vision condition, affecting an estimated 128 million people in the U.S. alone, presents a significant and growing market opportunity for effective treatment solutions.

The gradual loss of ability to focus on nearby objects is a natural part of aging, typically becoming noticeable in the early to mid-40s and continuing to worsen until around age 65. While traditional solutions include glasses and contact lenses, and surgical options involve incisional methods, Syntec Optics is leveraging its advanced optical manufacturing capabilities to support the development of a less invasive alternative.

"We are really glad for this opportunity to get involved early in the development, enabling optics for a product that creates a substantial demand for safer, quicker, effective, and convenient treatment options," said Matt Carey, head of business development and delivery at Syntec Optics. "We are proud to apply our decades of expertise in designing and manufacturing high-precision optics to support the clinical advancement of non-incisional solutions being developed by our customer. Our ability to produce complex optics is crucial for such innovative medical devices, and we believe this technology has the potential to improve the quality of life for millions significantly."

The global myopia and presbyopia treatment market was valued at USD 20.3 billion in 2025 and is projected to expand further, driven by the increasing prevalence of these conditions and the continuous demand for advanced treatments. Non-incisional optical solutions represent a promising segment within this market, offering the potential for reduced risk and quicker recovery times compared to traditional surgical interventions.

Next-generation treatments underscore Syntec Optics' commitment to advancing healthcare through manufacturing innovation. By providing critical optics manufacturing and precision expertise, the company is facilitating the development of technologies that can address unmet needs in the vision care market.

About Syntec Optics

Syntec Optics Holdings, Inc. (Nasdaq: OPTX), headquartered in Rochester, NY, is one of the largest custom and diverse end-market optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for mission-critical OEMs. Syntec Optics recently launched new products, including Low Earth Orbit (LEO) satellite optics for communication, lightweight night vision goggle optics for defense, biomedical optics for defense, and data center optics for Artificial Intelligence. To learn more, visit www.syntecoptics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, including certain financial forecasts and projections. All statements other than statements of historical fact contained in this press release, including statements as to the transactions contemplated by the business combination and related agreements, future results of operations and financial position, revenue and other metrics, planned products and services, business strategy and plans, objectives of management for future operations of Syntec Optics, market size, and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings including registration statement on Form S-4 filed with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.

For further information, please contact:

Tim Bechtold

Investor Relations

InvestorRelations@syntecoptics.com

SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)

FAQ

What is Syntec Optics (OPTX) developing for vision correction?

Syntec Optics is enabling optics for clinical development of non-incisional vision correction technology specifically targeting near vision (presbyopia) correction, offering a less invasive alternative to traditional surgical treatments.

What is the market size for Syntec Optics' (OPTX) vision correction technology?

The global myopia and presbyopia treatment market was valued at $20.3 billion in 2025, with approximately 128 million people affected by presbyopia in the U.S. alone.

How does Syntec Optics' (OPTX) vision correction technology differ from traditional treatments?

Syntec Optics' technology focuses on non-incisional vision correction, offering a potentially safer, quicker, and more convenient alternative to traditional surgical interventions and conventional solutions like glasses and contact lenses.

What is the target market for Syntec Optics' (OPTX) vision correction solution?

The technology targets people with age-related near vision problems (presbyopia), typically affecting individuals in their early to mid-40s and continuing until around age 65.